Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Topical cyclosporin A doesn't work for alopecia totalis because it doesn't penetrate the skin well.

This study found that oral cyclosporine was more effective and had fewer side effects than betamethasone minipulse therapy for treating alopecia areata.

This study found that corticosteroid pulse therapy may be more effective than oral cyclosporine with corticosteroid for patients with severe alopecia areata, especially for those with the plurifocal type or a short disease duration.

This study found that most chronic alopecia areata patients treated with azathioprine, methotrexate, or cyclosporine continued treatment for at least 12 months, often requiring concurrent low-dose prednisolone.

A kidney transplant patient on cyclosporin experienced unexpected severe hair loss, which improved with treatment adjustments.

In this study, cyclosporine A stimulated hair growth in mouse vibrissae organ culture by promoting matrix cell proliferation and altering growth factor expression.

This study found that cyclosporine A's enhancement of hair growth in mice is partly due to its ability to block the nuclear translocation of apoptosis-inducing factor, slowing the hair follicle transition to the catagen phase.

This study developed an advanced HPLC-ESI-ion trap MS(n) method for the structural identification of cyclosporin A analogs CyA and CyC and reported the first MS(n)-aided identification of a new CyA analog.

This study found that cyclosporine-A might significantly increase the risk of cerebral venous and arterial thrombosis in patients with aplastic anemia.

This review summarizes experimental studies on topical cyclosporin A for various skin conditions and reports no new clinical results; it also discusses the theoretical pharmacokinetics of topical application.

In this study, topical application of Cyclosporin A on mice skin induced hair growth by transitioning follicles from telogen to anagen, but no effect was observed on cultured human hair follicles.

This study observed that cyclosporine A significantly alters sex hormone levels in both pre- and post-menopausal women with primary biliary cirrhosis.

This study found that the cytochrome P450 enzyme CYP-sb21 can hydroxylate cyclosporine A at multiple positions, reducing its immunosuppressive effects but retaining its hair growth-promoting side-effect, and suggests modifications to improve regioselectivity for commercial use.

This study identified a cytochrome P450 enzyme, CYP-pa1 from Pseudonocardia autotrophica, as responsible for the specific hydroxylation of cyclosporin A at the 9th N-methyl leucine, suggesting potential for biotechnological applications.

In this case report, the authors highlight a 20-month-old girl with nephrotic syndrome who experienced severe alopecia due to an accidental high dose of cyclosporine; her hair regrew after the drug was stopped.

This study found that topical cyclosporin-A may lead to moderate recovery in patients with severe or refractory alopecia areata, particularly in focal type cases.

Oral cyclosporin doesn't stop hair loss.

This study suggests that the CsA-induced inactivation of the CaN/NFAT pathway may suppress TGF-β2 expression in dermal papilla cells, potentially contributing to CsA-associated hypertrichosis.

This study found that cyclosporin A stimulated hair growth in mouse vibrissae follicles by promoting cell proliferation, reducing apoptosis, and altering the expression of certain growth factor mRNAs.

This study demonstrated that cyclosporin A upregulated mRNA expression of HGF and VEGF in cultured mouse vibrissa follicles.

Cyclosporin A and FK506 can start new hair growth in mice, but ascomycin and rapamycin cannot.

Cyclosporin doesn't stop hair loss.

This article reviews the use of cyclosporine in dermatological conditions, noting its benefits in treating various skin diseases despite known adverse effects like nephrotoxicity and hypertension, and highlights its preferred use over other immunosuppressants due to an early therapeutic response and a good safety profile.

This study observed that cyclosporine showed a trend toward improving alopecia areata symptoms compared to placebo, but the difference was not statistically significant.

This study introduces a mouse model of cyclophosphamide-induced alopecia, which effectively replicates human chemotherapy-induced hair loss and can be pharmacologically manipulated to study hair regrowth patterns.

In this study, treating refractory alopecia universalis with low-dose cyclosporine A and prednisolone improved symptoms, with no recurring alopecia six months post-treatment and enhancements in immunologic function.

High doses of cyclosporine A increase testosterone conversion, possibly boosting hair growth.

In this case report, treatment with corticosteroid and cyclosporine improved hair growth in a 19-year-old male with alopecia universalis over 51 days.

In this report, a 65-year-old Omani male undergoing cyclosporine A treatment experienced hair repigmentation as a rare side effect.

This study found that cyclosporine A stimulates hair growth in a mouse model by preventing catagen development and increasing expression of certain growth factors.